ADC Therapeutics SA (ADCT) Stock Price

ADCTStock

$1.40−66.10%52W

Market Cap$178.73M

P/E—

PEG Ratio—

Div yield—

Beta1.84

ADCT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-73.64%

Price vs S&P 500 (4W)26.33%

VGM Score49.69

Book Value / Share (Quarterly)$0.47

P/TBV (Annual)3.97x

Revenue Growth (3Y)-27.09%

Cash Flow / Share (Quarterly)$-0.80

Price vs S&P 500 (YTD)-72.27%

Gross Margin (TTM)90.93%

Net Profit Margin (TTM)-121.77%

EPS (TTM)$-0.73

10-Day Avg Trading Volume2.23M

EPS Excl Extra (TTM)$-0.73

Revenue Growth (5Y)98.48%

EPS (Annual)$-1.12

ROI (Annual)-37.24%

Gross Margin (Annual)92.87%

Net Profit Margin (5Y Avg)-299.19%

Cash / Share (Quarterly)$1.72

Revenue Growth QoQ (YoY)2.17%

ROA (Last FY)-44.14%

Revenue Growth TTM (YoY)3.03%

EBITD / Share (TTM)$-0.70

ROE (5Y Avg)-117.97%

Operating Margin (TTM)-125.08%

Cash Flow / Share (Annual)$-1.12

P/B Ratio4.74x

P/B Ratio (Quarterly)4.17x

Net Income / Employee (Annual)$-758,600

EV / Revenue (TTM)4.72x

Net Interest Coverage (TTM)-2.26x

ROA (TTM)-32.75%

EPS Incl Extra (Annual)$-1.12

Current Ratio (Annual)4.37x

Quick Ratio (Quarterly)2.91x

3-Month Avg Trading Volume1.55M

52-Week Price Return-66.10%

Revenue / Employee (TTM)$423,300

Tangible BV / Share (Quarterly)$0.30

P/S Ratio (Annual)2.20x

Asset Turnover (Annual)0.25x

52-Week High$4.98

Operating Margin (5Y Avg)-284.41%

EPS Excl Extra (Annual)$-1.12

CapEx CAGR (5Y)-37.69%

Tangible BV CAGR (5Y)-21.14%

26-Week Price Return-63.73%

Quick Ratio (Annual)4.23x

13-Week Price Return3.70%

Total Debt / Equity (Annual)3.72x

Current Ratio (Quarterly)3.03x

Enterprise Value$375.79M

Revenue / Share Growth (5Y)89.29%

Asset Turnover (TTM)0.27x

Book Value / Share Growth (5Y)-19.47%

Revenue / Employee (Annual)$432,800

Inventory Turnover (Annual)0.51x

Pretax Margin (Annual)-174.06%

Cash / Share (Annual)$2.08

3-Month Return Std Dev93.66%

Gross Margin (5Y Avg)95.14%

Net Income / Employee (TTM)$-515,500

ROE (Last FY)-175.65%

Net Interest Coverage (Annual)-2.32x

EPS Basic Excl Extra (Annual)$-1.12

Receivables Turnover (TTM)2.94x

Total Debt / Equity (Quarterly)9.01x

EPS Incl Extra (TTM)$-0.73

Receivables Turnover (Annual)3.29x

ROI (TTM)-48.19%

P/S Ratio (TTM)2.25x

Pretax Margin (5Y Avg)-298.20%

Revenue / Share (Annual)$0.64

Tangible BV / Share (Annual)$0.92

Price vs S&P 500 (52W)-81.63%

Year-to-Date Return-60.34%

5-Day Price Return-24.73%

EPS Normalized (Annual)$-1.12

ROA (5Y Avg)-45.50%

Net Profit Margin (Annual)-175.31%

Month-to-Date Return14.75%

Cash Flow / Share (TTM)$-2.16

EBITD / Share (Annual)$-0.95

Operating Margin (Annual)-149.34%

LT Debt / Equity (Annual)3.49x

ROI (5Y Avg)-69.52%

LT Debt / Equity (Quarterly)8.32x

EPS Basic Excl Extra (TTM)$-0.73

P/TBV (Quarterly)6.53x

P/B Ratio (Annual)3.33x

Inventory Turnover (TTM)0.64x

Pretax Margin (TTM)-122.28%

Book Value / Share (Annual)$1.10

Price vs S&P 500 (13W)1.02%

Beta1.84x

Revenue / Share (TTM)$0.51

ROE (TTM)-229.23%

52-Week Low$0.78

vGradeC

gGradeB

mGradeD

vgmGradeC

ADCT Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.22	-$0.11	+49.07%(+$0.11)
Q1 2026	May 4, 2026	-$0.20	-$0.21	-4.13%(-$0.01)
Q4 2025	Mar 10, 2026	-$0.27	-$0.04	+85.09%(+$0.23)
Q3 2025	Nov 10, 2025	-$0.36	-$0.30	+17.43%(+$0.06)
Q2 2025	Aug 12, 2025	-$0.48	-$0.50	-4.89%(-$0.02)

ADCT Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.33

3.83

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ADCTADC Therapeutics SA	C	B	D	2.2x	3.0%	90.9%	—	$1.40
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About ADC Therapeutics SA

ADC Therapeutics is an oncology-focused biotechnology company with an FDA-approved product, ZYNLONTA, for relapsed or refractory large B-cell lymphoma. The company develops antibody-drug conjugates (ADCs) targeting hematological malignancies and solid tumors, supported by a pipeline of candidates across multiple mechanisms. Revenue is generated primarily from the United States and Europe.